{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T17:22:06Z","timestamp":1770139326011,"version":"3.49.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,2]]},"DOI":"10.7759\/cureus.102862","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T05:54:37Z","timestamp":1770098077000},"source":"Crossref","is-referenced-by-count":0,"title":["Peripheral Lymphocyte Dynamics in the Immune Microenvironment of Multiple Myeloma During Autologous Stem Cell Transplantation"],"prefix":"10.7759","author":[{"given":"Carlos Agustin","family":"Villegas-Valverde","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Imilla","family":"Casado-Hernandez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Sotomayor-Lugo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yandy M","family":"Castillo-Aleman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatma","family":"Abdou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shadi","family":"Sharif-Shamat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio A","family":"Bencomo-Hernandez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yendry","family":"Ventura-Carmenate","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.46","article-title":"Multiple myeloma","volume":"3","author":"Kumar SK","year":"2017","unstructured":"Kumar SK, Rajkumar V, Kyle RA, et al.. Multiple myeloma. Nat Rev Dis Primers. 2017, 3:17046. 10.1038\/nrdp.2017.46","journal-title":"Nat Rev Dis Primers"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.2128","article-title":"Global burden of multiple myeloma: a systematic analysis for the Global Burden of Disease Study 2016","volume":"4","author":"Cowan AJ","year":"2018","unstructured":"Cowan AJ, Allen C, Barac A, et al.. Global burden of multiple myeloma: a systematic analysis for the Global Burden of Disease Study 2016. JAMA Oncol. 2018, 4:1221-7. 10.1001\/jamaoncol.2018.2128","journal-title":"JAMA Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray F","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024, 74:229-63. 10.3322\/caac.21834","journal-title":"CA Cancer J Clin"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26590","article-title":"Multiple myeloma: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Rajkumar SV","year":"2022","unstructured":"Rajkumar SV. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. Am J Hematol. 2022, 97:1086-107. 10.1002\/ajh.26590","journal-title":"Am J Hematol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-128769","article-title":"First review of multiple myeloma patients in Sheikh Khalifa Medical City, Abu Dhabi, United Arab Emirates","volume":"134","author":"Abu Haleeqa M","year":"2019","unstructured":"Abu Haleeqa M, Alkaabi F, Janodi R, Raidullah E. First review of multiple myeloma patients in Sheikh Khalifa Medical City, Abu Dhabi, United Arab Emirates. Blood. 2019, 134:5587. 10.1182\/blood-2019-128769","journal-title":"Blood"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1172\/JCI129205","article-title":"Immunotherapy of multiple myeloma","volume":"130","author":"Minnie SA","year":"2020","unstructured":"Minnie SA, Hill GR. Immunotherapy of multiple myeloma. J Clin Invest. 2020, 130:1565-75. 10.1172\/JCI129205","journal-title":"J Clin Invest"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2016.122","article-title":"Genomic complexity of multiple myeloma and its clinical implications","volume":"14","author":"Manier S","year":"2017","unstructured":"Manier S, Salem KZ, Park J, Landau DA, Getz G, Ghobrial IM. Genomic complexity of multiple myeloma and its clinical implications. Nat Rev Clin Oncol. 2017, 14:100-13. 10.1038\/nrclinonc.2016.122","journal-title":"Nat Rev Clin Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1172\/JCI61188","article-title":"Molecular pathogenesis of multiple myeloma and its premalignant precursor","volume":"122","author":"Kuehl WM","year":"2012","unstructured":"Kuehl WM, Bergsagel PL. Molecular pathogenesis of multiple myeloma and its premalignant precursor. J Clin Invest. 2012, 122:3456-63. 10.1172\/JCI61188","journal-title":"J Clin Invest"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019003727","article-title":"Myeloma escape after stem cell transplantation is a consequence of T-cell exhaustion and is prevented by TIGIT blockade","volume":"134","author":"Minnie SA","year":"2019","unstructured":"Minnie SA, Kuns RD, Gartlan KH, et al.. Myeloma escape after stem cell transplantation is a consequence of T-cell exhaustion and is prevented by TIGIT blockade. Blood. 2019, 134:1878. 10.1182\/blood.2019003727","journal-title":"Blood"},{"key":"ref10","article-title":"Guidelines for performing single-platform absolute CD4+ T-cell determinations with CD45 gating for persons infected with human immunodeficiency virus. Centers for Disease Control and Prevention","volume":"52","author":"Mandy FF","year":"2003","unstructured":"Mandy FF, Nicholson JK, McDougal JS. Guidelines for performing single-platform absolute CD4+ T-cell determinations with CD45 gating for persons infected with human immunodeficiency virus. Centers for Disease Control and Prevention. MMWR Recomm Rep. 2003, 52:1-13.","journal-title":"MMWR Recomm Rep"},{"key":"ref11","article-title":"Assay development and validation of T, B, and NK lymphocyte subset enumeration","volume":"4","author":"Illingworth A","year":"2024","unstructured":"Illingworth A, Al-Attar A, League S. Assay development and validation of T, B, and NK lymphocyte subset enumeration. ICCS. 2024, 4:4-6.","journal-title":"ICCS"},{"key":"ref12","article-title":"Reference ranges for lymphocyte subsets in healthy adult male Omanis","volume":"29","author":"Al-Jabri AA","year":"2008","unstructured":"Al-Jabri AA, Al-Shukaili AK, Al-Rashdi ZT, Ganguly SS. Reference ranges for lymphocyte subsets in healthy adult male Omanis. Saudi Med J. 2008, 29:409-12.","journal-title":"Saudi Med J"},{"key":"ref13","article-title":"Normal range determination of lymphocytes subsets in normal adults in Iran","volume":"10","author":"Shokouhi Shoormasti R","year":"2011","unstructured":"Shokouhi Shoormasti R, Azimdoost A, Saghafi S, Movahhedi M, Haghi Ashtiani MT, Pourpak Z, Bagher Eslami M. Normal range determination of lymphocytes subsets in normal adults in Iran. Iran J Allergy Asthma Immunol. 2011, 10:295-8.","journal-title":"Iran J Allergy Asthma Immunol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.2217\/bmm.14.83","article-title":"Reference ranges of lymphocyte subsets in healthy Qatari adults","volume":"9","author":"Al-Thani A","year":"2015","unstructured":"Al-Thani A, Hamdi WS, Al-Marwani A, Alnaqdy A, Sharafeldin H. Reference ranges of lymphocyte subsets in healthy Qatari adults. Biomark Med. 2015, 9:443-52. 10.2217\/bmm.14.83","journal-title":"Biomark Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1159\/000084638","article-title":"Reference ranges of lymphocyte subsets of healthy adults in Turkey","volume":"14","author":"Yaman A","year":"2005","unstructured":"Yaman A, Cetiner S, Kibar F, Ta\u015fova Y, Seydao\u011flu G, D\u00fcndar IH. Reference ranges of lymphocyte subsets of healthy adults in Turkey. Med Princ Pract. 2005, 14:189-93. 10.1159\/000084638","journal-title":"Med Princ Pract"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1177\/0300060520913149","article-title":"Characteristics of and reference ranges for peripheral blood lymphocytes and CD4+ T cell subsets in healthy adults in Shanxi Province, North China","volume":"48","author":"Xu D","year":"2020","unstructured":"Xu D, Wu Y, Gao C, et al.. Characteristics of and reference ranges for peripheral blood lymphocytes and CD4+ T cell subsets in healthy adults in Shanxi Province, North China. J Int Med Res. 2020, 48:300060520913149. 10.1177\/0300060520913149","journal-title":"J Int Med Res"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.imbio.2014.02.010","article-title":"Reference ranges of lymphocyte subsets in healthy adults and adolescents with special mention of T cell maturation subsets in adults of South Florida","volume":"219","author":"Valiathan R","year":"2014","unstructured":"Valiathan R, Deeb K, Diamante M, Ashman M, Sachdeva N, Asthana D. Reference ranges of lymphocyte subsets in healthy adults and adolescents with special mention of T cell maturation subsets in adults of South Florida. Immunobiology. 2014, 219:487-96. 10.1016\/j.imbio.2014.02.010","journal-title":"Immunobiology"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3390\/cells11142197","article-title":"The impact of infused autograft absolute numbers of immune effector cells on survival post-autologous stem cell transplantation","volume":"11","author":"Porrata LF","year":"2022","unstructured":"Porrata LF. The impact of infused autograft absolute numbers of immune effector cells on survival post-autologous stem cell transplantation. Cells. 2022, 11:26-8. 10.3390\/cells11142197","journal-title":"Cells"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1111\/trf.16424","article-title":"Autograft cellular composition and outcome in myeloma patients: results of the prospective multicenter GOA study","volume":"61","author":"Turunen A","year":"2021","unstructured":"Turunen A, Silvennoinen R, Partanen A, et al.. Autograft cellular composition and outcome in myeloma patients: results of the prospective multicenter GOA study. Transfusion. 2021, 61:1830-44. 10.1111\/trf.16424","journal-title":"Transfusion"},{"key":"ref20","unstructured":"ACS key statistics about multiple myeloma. (2025). Accessed. February 7, 2025: https:\/\/www.cancer.org\/cancer\/types\/multiple-myeloma.html."},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3390\/life14040461","article-title":"Role of immune cells and immunotherapy in multiple myeloma","volume":"14","author":"Radhakrishnan V","year":"2024","unstructured":"Radhakrishnan V, Golla U, Kudva AK. Role of immune cells and immunotherapy in multiple myeloma. Life (Basel). 2024, 14:32-4. 10.3390\/life14040461","journal-title":"Life (Basel)"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.663748","article-title":"Predictive role of immune profiling for survival of multiple myeloma patients","volume":"12","author":"Zhaoyun L","year":"2021","unstructured":"Zhaoyun L, Rong F. Predictive role of immune profiling for survival of multiple myeloma patients. Front Immunol. 2021, 12:663748. 10.3389\/fimmu.2021.663748","journal-title":"Front Immunol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.404","article-title":"Long-term outcome of immunologic autograft engineering","volume":"3","author":"Porrata LF","year":"2022","unstructured":"Porrata LF, Inwards DJ, Ansell SM, et al.. Long-term outcome of immunologic autograft engineering. EJHaem. 2022, 3:488-91. 10.1002\/jha2.404","journal-title":"EJHaem"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066","article-title":"T-cell exhaustion in multiple myeloma relapse after autotransplant: optimal timing of immunotherapy","volume":"4","author":"Chung DJ","year":"2016","unstructured":"Chung DJ, Pronschinske KB, Shyer JA, et al.. T-cell exhaustion in multiple myeloma relapse after autotransplant: optimal timing of immunotherapy. Cancer Immunol Res. 2016, 4:61-71. 10.1158\/2326-6066","journal-title":"Cancer Immunol Res"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017005447","article-title":"Immune signatures associated with improved progression-free and overall survival for myeloma patients treated with AHSCT","volume":"1","author":"Ho CM","year":"2017","unstructured":"Ho CM, McCarthy PL, Wallace PK, et al.. Immune signatures associated with improved progression-free and overall survival for myeloma patients treated with AHSCT. Blood Adv. 2017, 1:1056-66. 10.1182\/bloodadvances.2017005447","journal-title":"Blood Adv"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12985","article-title":"Reconstitution of immune cell populations in multiple sclerosis patients after autologous stem cell transplantation","volume":"189","author":"Karnell FG","year":"2017","unstructured":"Karnell FG, Lin D, Motley S, et al.. Reconstitution of immune cell populations in multiple sclerosis patients after autologous stem cell transplantation. Clin Exp Immunol. 2017, 189:268-78. 10.1111\/cei.12985","journal-title":"Clin Exp Immunol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2021.10.001","article-title":"Novel cell and immune engagers in optimizing tumor- specific immunity post-autologous transplantation in multiple myeloma","volume":"28","author":"Janakiram M","year":"2022","unstructured":"Janakiram M, Arora N, Bachanova V, Miller JS. Novel cell and immune engagers in optimizing tumor- specific immunity post-autologous transplantation in multiple myeloma. Transplant Cell Ther. 2022, 28:61-9. 10.1016\/j.jtct.2021.10.001","journal-title":"Transplant Cell Ther"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-84047-2","article-title":"Analysis of early efficacy and immune reconstitution after autologous hematopoietic stem cell transplantation in multiple myeloma","volume":"15","author":"Chen K","year":"2025","unstructured":"Chen K, Liang H, Yu Z, et al.. Analysis of early efficacy and immune reconstitution after autologous hematopoietic stem cell transplantation in multiple myeloma. Sci Rep. 2025, 15:1222. 10.1038\/s41598-024-84047-2","journal-title":"Sci Rep"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.736137","article-title":"CD4+ T cell dependent B cell recovery and function after autologous hematopoietic stem cell transplantation","volume":"12","author":"Heck C","year":"2021","unstructured":"Heck C, Steiner S, Kaebisch EM, et al.. CD4+ T cell dependent B cell recovery and function after autologous hematopoietic stem cell transplantation. Front Immunol. 2021, 12:736137. 10.3389\/fimmu.2021.736137","journal-title":"Front Immunol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1080\/1042819031000077089","article-title":"Re-infused autologous graft natural killer cells correlates with absolute lymphocyte count recovery after autologous stem cell transplantation","volume":"44","author":"Porrata LF","year":"2003","unstructured":"Porrata LF, Gastineau DA, Padley D, Bundy K, Markovic SN. Re-infused autologous graft natural killer cells correlates with absolute lymphocyte count recovery after autologous stem cell transplantation. Leuk Lymphoma. 2003, 44:997-1000. 10.1080\/1042819031000077089","journal-title":"Leuk Lymphoma"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.3390\/medsci2020082","article-title":"NKT cell responses to B cell lymphoma","volume":"2","author":"Li J","year":"2014","unstructured":"Li J, Sun W, Subrahmanyam PB, et al.. NKT cell responses to B cell lymphoma. Med Sci (Basel). 2014, 2:82-97. 10.3390\/medsci2020082","journal-title":"Med Sci (Basel)"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.32","article-title":"The cellular immune system in myelomagenesis: NK cells and T cells in the development of myeloma [corrected] and their uses in immunotherapies","volume":"5","author":"Dosani T","year":"2015","unstructured":"Dosani T, Carlsten M, Maric I, Landgren O. The cellular immune system in myelomagenesis: NK cells and T cells in the development of myeloma [corrected] and their uses in immunotherapies. Blood Cancer J. 2015, 5:e306. 10.1038\/bcj.2015.32","journal-title":"Blood Cancer J"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.1RU0814-382","article-title":"CD4+\/CD8+ double-positive T cells: more than just a developmental stage?","volume":"97","author":"Overgaard NH","year":"2015","unstructured":"Overgaard NH, Jung JW, Steptoe RJ, Wells JW. CD4+\/CD8+ double-positive T cells: more than just a developmental stage?. J Leukoc Biol. 2015, 97:31-8. 10.1189\/jlb.1RU0814-382","journal-title":"J Leukoc Biol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.6015","article-title":"Preliminary analysis of double-negative T, double-positive T, and natural killer T-like cells in B-cell chronic lymphocytic leukemia","volume":"12","author":"Valvano L","year":"2023","unstructured":"Valvano L, Nozza F, D'Arena G, et al.. Preliminary analysis of double-negative T, double-positive T, and natural killer T-like cells in B-cell chronic lymphocytic leukemia. Cancer Med. 2023, 12:13241-55. 10.1002\/cam4.6015","journal-title":"Cancer Med"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-2291","article-title":"Developing allogeneic double-negative T cells as a novel off-the-shelf adoptive cellular therapy for cancer","volume":"25","author":"Lee JB","year":"2019","unstructured":"Lee JB, Kang H, Fang L, D'Souza C, Adeyi O, Zhang L. Developing allogeneic double-negative T cells as a novel off-the-shelf adoptive cellular therapy for cancer. Clin Cancer Res. 2019, 25:2241-53. 10.1158\/1078-0432.CCR-18-2291","journal-title":"Clin Cancer Res"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.7150\/jca.39717","article-title":"DNT cell-based immunotherapy: progress and applications","volume":"11","author":"Li Y","year":"2020","unstructured":"Li Y, Dong K, Fan X, Xie J, Wang M, Fu S, Li Q. DNT cell-based immunotherapy: progress and applications. J Cancer. 2020, 11:3717-24. 10.7150\/jca.39717","journal-title":"J Cancer"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/403706-peripheral-lymphocyte-dynamics-in-the-immune-microenvironment-of-multiple-myeloma-during-autologous-stem-cell-transplantation","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T05:54:39Z","timestamp":1770098079000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/403706-peripheral-lymphocyte-dynamics-in-the-immune-microenvironment-of-multiple-myeloma-during-autologous-stem-cell-transplantation"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,2]]},"references-count":36,"URL":"https:\/\/doi.org\/10.7759\/cureus.102862","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2,2]]}}}